SOUTH SAN FRANCISCO, Calif., May 22, 2007 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on advancing cancer care, today announced the promotion of Hana B. Moran, Ph.D. to Vice President, Regulatory Affairs and Quality Assurance.
"Dr. Moran's outstanding experience and achievements in the biopharmaceutical industry generally, and regulatory and clinical affairs specifically, have significantly contributed to moving our company forward," stated Mark Ahn, President and CEO. "We look forward to her continued guidance and leadership as we advance multiple oncology and supportive care therapeutics through clinical development and commercialization."
Dr. Moran joined Hana Biosciences in December 2006 as a Senior Director, Regulatory Affairs and Quality Assurance. Dr. Moran has more than 24 years of pharmaceutical industry experience in research, regulatory affairs, and quality assurance in start-up and high growth companies including Sangstat, Scios, Athena, and Intarcia. She led marketing approvals for nine pharmaceutical products, including drugs, biologics, medical devices and in vitro diagnostics globally, including oncology. Dr. Moran earned an MSc in Chemical Engineering from Slovak Technical University, Bratislava, Slovakia and a Ph.D. in Organic Chemistry from the Weizmann Institute of Science, Rehovoth, Israel.
About Hana Biosciences, Inc.
Hana Biosciences, Inc. (Nasdaq:HNAB) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to advance cancer care. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Hana Biosciences can be found at www.hanabiosciences.com.
The Hana Biosciences, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3290
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that could cause Hana's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Hana's development efforts relating to its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of Hana's product candidates, risks that Hana's timelines for development of its product candidates may not occur as planned, the risk that the results of clinical trials may not support Hana's claims, Hana's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's Annual Report on Form 10-K for the year ended December 31, 2006 filed with the Securities and Exchange Commission. Hana assumes no obligation to update these statements, except as required by law.